埃布塞伦通过抑制YTHDF1-介导的c-Fos表达来抑制乳腺癌瘤发生
Arathy Vasukutty1, Poshan Yugal Bhattarai1, Hong Seok Choi1
1Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea.
YTHDF1抑制剂ebselen在乳腺癌治疗方面显示出有前途. 通过向YTHDF1-介导的FOS mRNA转化,Ebselen降低了癌细胞活力,诱导了亡,并抑制了瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- YTHDF1,一种N6-甲基氨酸 (m6A) 结合蛋白,与乳腺癌的进展有关.
- 向YTHDF1为乳腺癌提供了一个尚未探索的治疗策略.
研究的目的:
- 为了研究新型YTHDF1抑制剂ebselen在乳腺癌细胞中的抗癌作用.
- 阐明EBSELEN作用的潜在分子机制.
主要方法:
- 细胞活力测试,Annexin V染色,Sub-G1积累和DNA碎片化测试被用于评估细胞亡.
- 测量了反应性氧物种 (ROS) 生产和自诱导.
- 分析了FOS mRNA稳定,翻译和c-Fos表达.
- 在实验室中采用了独立于固的生长和体内正位素的小鼠模型.
主要成果:
- 埃布塞伦治疗降低了乳腺癌细胞活力,并以剂量依赖的方式诱导了亡.
- 埃布塞伦增加了ROS的产生和自功能受损.
- 该药物抑制了YTHDF1介导的FOS mRNA稳定和翻译,降低了c-Fos表达.
- 埃布塞伦在试验室和 орто托普小鼠模型中抑制了瘤生长.
结论:
- YTHDF1是乳腺癌的可行的治疗点.
- 埃布塞伦显示出显著的抗癌活性,并值得进一步研究,作为乳腺癌治疗的潜在小分子抑制剂.
更多相关视频
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
相关概念视频
Mitogens and the Cell Cycle
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Cell Specific Gene Expression
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
